SRSF2 and acute myeloid leukemia: Across healthy donors, SRSF2-WT AML, and SRSF2-mutant AML, the mutant group showed higher DSS to CHK1 inhibitors, prexasertib (Figure 2C) and PF-00477736 (Figure 2D), and to the WEE1 inhibitor adavosertib (Figure 2E).